798 PROGNOSTIC ROLE OF MICRORNA 221 IN HIGH RISK PROSTATE CANCER

You have accessJournal of UrologyProstate Cancer: Basic Research (IV)1 Apr 2013798 PROGNOSTIC ROLE OF MICRORNA 221 IN HIGH RISK PROSTATE CANCER Paolo Gontero, Andrea Zitella, Kneitz Burkhard, Donatella Pacchioni, Simone Giona, Francesca Peraldo, Alberto Briganti, Joniau Steven, Karnes Jeffrey, and Martin Spahn Paolo GonteroPaolo Gontero Turin, Italy More articles by this author , Andrea ZitellaAndrea Zitella Torino, Italy More articles by this author , Kneitz BurkhardKneitz Burkhard Würzburg, Germany More articles by this author , Donatella PacchioniDonatella Pacchioni Turin, Italy More articles by this author , Simone GionaSimone Giona Turin, Italy More articles by this author , Francesca PeraldoFrancesca Peraldo Turin, Italy More articles by this author , Alberto BrigantiAlberto Briganti Milan, Italy More articles by this author , Joniau StevenJoniau Steven Leuven, Belgium More articles by this author , Karnes JeffreyKarnes Jeffrey Rochester, MN More articles by this author , and Martin SpahnMartin Spahn Bern, Switzerland More articles by this author View All Author Informationhttps://doi.org/10.1016/j.juro.2013.02.362AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookTwitterLinked InEmail INTRODUCTION AND OBJECTIVES The microRNA 221 (miR-221) is downregulated in more aggressive prostate cancer compared to less aggressive. We present a case control clinical study aimed at finding a prognostic value of miR-221 expression in a cohort of patients surgically treated for high risk PCa. METHODS A group of consecutive patients that had a radical prostatectomy for high risk PCa between 2003 and 2011 was considered. A single uropathologist reviewed the prostatectomy slides to select areas containing 90% of cancer in 1 square centimeter. A macrodissection of the paraffin embedded tissue was performed in order to obtain the material for RNA extraction and miR-221 quantification (normalized for microRNA RNU6b). The data obtained were compared to clinical, pathological and immunohistochemical (KI67 and topoisomeraseII staining) prognostic factors. The outcome considered were biochemical recurrence (BCR) and clinical recurrence (CF). Cancer specific survival and overall survival were not computed due to the small number of event at the moment. All the distributions of continuous variables between recurred and not recurred groups were compared using non parametric Wilcoxon two sample test. Fisher exact test was used to compare categorical variable. RESULTS 71 patients, mean follow up 42 months (5-143), 22 BCR, 9 CF, 3 deaths (2 cancer specific and 1 of other cancer). Mean age 65.6±6.2 years; mean PSA 26.2±27 ng/ml; 65% had a path. Gleason >7; 79% had a path. stage 3 or 4; 33% had positive nodes; 43% had positive surgical margins and 37% had seminal vesicles invasion (SVI). 36% received adjuvant hormonal therapy (HT) and 35% received adjuvant radiotherapy (RT). There were no differences in distribution of age, PSA, positive lymph node number, percentage of positive lymph nodes, KI67 staining, Topoisomerase-II staining, Gleason, stage, SVI, margins, adjuvant HT and adjuvant RT between patients with or without BCR. The only significant difference was the miR-221 expression: mean 2.6±1.4 in not recurred and 1.6±1.5 in BCR (p = 0.019). A similar trend was observed considering the CF as outcome but no statistical significance could be showed due to the low number of event (9CF). miR-221 expression in not recurred 2.4±1.4 versus 1.5±1.9 in CF (p = 0.15). These results were confirmed in a multivariate logistic regression model considering as independent variables Gleason, PSA, stage, SVI, immunohistochemical staining, miR-221: odds ratio for miR-221: 0.58 (0.34-0.98 CI). CONCLUSIONS These preliminary results show an extraordinary independent prognostic value for miR-221 down regulation in a group of otherwise homogeneous high risk PCa. © 2013 by American Urological Association Education and Research, Inc.FiguresReferencesRelatedDetails Volume 189Issue 4SApril 2013Page: e328-e329 Advertisement Copyright & Permissions© 2013 by American Urological Association Education and Research, Inc.MetricsAuthor Information Paolo Gontero Turin, Italy More articles by this author Andrea Zitella Torino, Italy More articles by this author Kneitz Burkhard Würzburg, Germany More articles by this author Donatella Pacchioni Turin, Italy More articles by this author Simone Giona Turin, Italy More articles by this author Francesca Peraldo Turin, Italy More articles by this author Alberto Briganti Milan, Italy More articles by this author Joniau Steven Leuven, Belgium More articles by this author Karnes Jeffrey Rochester, MN More articles by this author Martin Spahn Bern, Switzerland More articles by this author Expand All Advertisement Advertisement PDF downloadLoading ...